Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024.
加利福尼亚库比蒂诺，2024年9月4日（环球新闻社） - Reviva Pharmaceuticals Holdings, Inc.（纳斯达克：RVPH）（“Reviva”或“公司”），一家处于后期阶段的药品公司，开发旨在解决中枢神经系统（CNS）、炎症和心脏代谢疾病领域未满医疗需求的疗法，今天宣布，Reviva的创始人、总裁兼首席执行官拉克仔林纳兰·巴特（Laxminarayan Bhat）博士将出席2024年9月9日至11日举行的H.C. Wainwright第26届全球投资大会。
H.C. Wainwright 26th Annual Global Investment Conference
Format: Corporate update
Date/Time: Pre-recorded presentation available on-demand Monday, September 9, at 7:00 a.m. ET
Webcast Link: Click Here
H.C. Wainwright第26届全球投资者会议
格式：企业更新
日期/时间：预录制演示将于东部时间9月9日星期一上午7点提供随时观看的服务。
网络直播链接：点击这里
Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your H.C. Wainwright sales representative to register for the conference.
管理层还将参加在整个活动期间举行的虚拟一对一会议。要安排与管理层的会议，请联系您的H.C. Wainwright销售代表注册参加会议。
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Reviva是一家后期生物制药公司，致力于为代表医学需求和对社会、患者及其家人造成负担的疾病开发、发现和寻求商业化的下一代治疗方案。 Reviva目前的产品管道集中于中枢神经、呼吸和代谢类疾病。Reviva的产品管道目前包括两种药物候选，即Brilaroxazine（RP5063）和RP1208。两者均是公司内部自行发现的新型化学实体。 Reviva已在美国，欧洲和其他几个国家获得了Brilaroxazine和RP1208的组成专利权。
Reviva是一家晚期生物制药公司，致力于发现、开发并寻求商业化对于社会、患者及其家庭构成医疗需求和负担的下一代治疗方法。Reviva的当前管线专注于中枢神经系统(CNS)、炎症和心血管代谢疾病。Reviva目前的管线包括两个药物候选，即布瑞拉洛昔(RP5063)和RP1208。两者均是公司在内部发现的新化学物质。Reviva已在美国、欧洲和其他几个国家获得了布瑞拉洛昔和RP1208的构成专利权。
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
公司联系人:
Reviva Pharmaceuticals Holdings，Inc.
Laxminarayan Bhat，博士
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
投资者关系联系人：
LifeSci Advisors，LLC
Bruce Mackle
bmackle@lifesciadvisors.com
Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783
媒体联系人：
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783